IL193306A - Use of Enhanced Forms of Factor V in the Preparation of Medicines to Treat Hemostasis-Related Disorders and Isolated Nucleic Acid Molecules Encoded into These Enhanced Forms - Google Patents

Use of Enhanced Forms of Factor V in the Preparation of Medicines to Treat Hemostasis-Related Disorders and Isolated Nucleic Acid Molecules Encoded into These Enhanced Forms

Info

Publication number
IL193306A
IL193306A IL193306A IL19330608A IL193306A IL 193306 A IL193306 A IL 193306A IL 193306 A IL193306 A IL 193306A IL 19330608 A IL19330608 A IL 19330608A IL 193306 A IL193306 A IL 193306A
Authority
IL
Israel
Prior art keywords
activated forms
medicaments
factor
preparation
nucleic acid
Prior art date
Application number
IL193306A
Other languages
English (en)
Hebrew (he)
Other versions
IL193306A0 (en
Original Assignee
Philadelphia Children Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philadelphia Children Hospital filed Critical Philadelphia Children Hospital
Publication of IL193306A0 publication Critical patent/IL193306A0/en
Publication of IL193306A publication Critical patent/IL193306A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL193306A 2006-02-23 2008-08-07 Use of Enhanced Forms of Factor V in the Preparation of Medicines to Treat Hemostasis-Related Disorders and Isolated Nucleic Acid Molecules Encoded into These Enhanced Forms IL193306A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77612406P 2006-02-23 2006-02-23
PCT/US2007/062720 WO2007101106A2 (en) 2006-02-23 2007-02-23 Compositions and methods for modulating hemostasis using variant forms of activated factor v

Publications (2)

Publication Number Publication Date
IL193306A0 IL193306A0 (en) 2011-08-01
IL193306A true IL193306A (en) 2013-04-30

Family

ID=38459752

Family Applications (1)

Application Number Title Priority Date Filing Date
IL193306A IL193306A (en) 2006-02-23 2008-08-07 Use of Enhanced Forms of Factor V in the Preparation of Medicines to Treat Hemostasis-Related Disorders and Isolated Nucleic Acid Molecules Encoded into These Enhanced Forms

Country Status (7)

Country Link
US (2) US8236764B2 (https=)
EP (2) EP1986681A4 (https=)
JP (1) JP2009528293A (https=)
AU (1) AU2007220825B2 (https=)
CA (1) CA2641519A1 (https=)
IL (1) IL193306A (https=)
WO (1) WO2007101106A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012509670A (ja) 2008-11-21 2012-04-26 ザ チルドレンズ ホスピタル オブ フィラデルフィア 血液凝固促進剤としてのヘビ第五因子及び使用方法
US20120065137A1 (en) * 2010-09-03 2012-03-15 Richard Jenny Therapeutics for trauma induced factor v consumptive coagulopathy
US8637448B2 (en) 2010-09-14 2014-01-28 University Of Rochester Recombinant factor VIII having enhanced stability following mutation at the A1-C2 domain interface
WO2013056221A1 (en) * 2011-10-13 2013-04-18 The Children's Hospital Of Philadelphia Compositions and methods for modulating thrombin generation
AR101185A1 (es) * 2014-07-11 2016-11-30 Novo Nordiks As Anticuerpos anti-factor v o factor v activado
CA3077084A1 (en) 2017-10-05 2019-04-11 Epivax, Inc. Regulatory t cell epitopes
WO2019210187A1 (en) * 2018-04-26 2019-10-31 The University Of North Carolina At Chapel Hill Methods and compositions for treatment of hemophilia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093699A (en) 1987-07-09 2000-07-25 The University Of Manitoba Method for gene therapy involving suppression of an immune response
WO1994017810A1 (en) 1993-02-12 1994-08-18 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
WO1994023744A1 (en) 1993-04-16 1994-10-27 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
AU7676894A (en) 1993-08-27 1995-03-21 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Convection-enhanced drug delivery
AT401270B (de) 1994-09-26 1996-07-25 Immuno Ag Verfahren zur quantifizierung von genomischer dna
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
WO1996026742A1 (en) 1995-02-28 1996-09-06 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US6228646B1 (en) 1996-03-07 2001-05-08 The Regents Of The University Of California Helper-free, totally defective adenovirus for gene therapy
AU2003241599A1 (en) 2002-05-22 2003-12-12 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of hemophilia a

Also Published As

Publication number Publication date
EP1986681A2 (en) 2008-11-05
EP1986681A4 (en) 2010-08-04
AU2007220825B2 (en) 2013-02-21
AU2007220825A1 (en) 2007-09-07
EP2384764A2 (en) 2011-11-09
WO2007101106A2 (en) 2007-09-07
WO2007101106A3 (en) 2008-11-27
EP2384764A3 (en) 2012-02-08
IL193306A0 (en) 2011-08-01
JP2009528293A (ja) 2009-08-06
US20120288895A1 (en) 2012-11-15
US8470557B2 (en) 2013-06-25
CA2641519A1 (en) 2007-09-07
US8236764B2 (en) 2012-08-07
US20090318344A1 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
IL178775A (en) Pharmaceuticals containing glucocorticoid for use in the treatment of disorders requiring acute glucocorticoid therapy
ZA200806114B (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
ZA200902409B (en) Lingo binding molecules and pharmaceutical use thereof
IL209267A (en) Combinations containing methotrexate and dhodh inhibitors and their use in the preparation of the drug
IL191310A (en) A variant of the factor xa enhancer hemostasis, a pharmaceutical product containing it, and its use in the preparation of drugs for the treatment of hemostasis-related diseases
IL193762A (en) The effective compounds in inhibiting dgat1-related disorders, their medicinal products and their use in the preparation of drugs
IL206296A (en) History of aminopyrazole, and their medicinal products and their use in the preparation of drugs for the prevention and treatment of diseases
IL188113A (en) Nucleic acid structures encoded with intersectional responses of psma288–297 and prame425–433, or analogs having their intersecting reaction and their use in the preparation of cancer drugs for nucleic acid structures encoded for psma288–297 and prame425–433 cross-reactors Their intersecting response and their use in the preparation of cancer treatment drugs
IL193936A0 (en) Compositions and methods for the treatment of immunoinflammatory disorders
SI2390255T1 (sl) Novi aminoglikozidi in njihove uporabe pri zdravljenju genetskih motenj
IL206690A0 (en) Protein kinase inhibitors and their use in the preparation of medicaments
EP1912634A4 (en) PREPARATION AND USE OF BIPHENYL AMINOACIDAL DERIVATIVES TO TREAT OBESITY
IL211842A (en) Antibodies or fragments of their human tgfbrii, pharmacological preparations containing them and their use in the preparation of a drug for inhibiting anogenesis
IL193306A (en) Use of Enhanced Forms of Factor V in the Preparation of Medicines to Treat Hemostasis-Related Disorders and Isolated Nucleic Acid Molecules Encoded into These Enhanced Forms
IL204741A (en) Ceramide History for the Treatment of Multiple Cyst Diseases and Pharmaceuticals Containing These History
IL211459A0 (en) Pancreatic polypeptide and variants thereof for use in the treatment of intestinal disorders
GB2458868B (en) Fluphenazine based combination for use in the treatment of protein aggregation diseases
EP1993523A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROTEIN AGGREGATION DISORDERS
ZA201001207B (en) Therapeutic formulations for the treatment of cold and flu-like symptoms
IL195155A (en) Dosage form for delayed glucocorticoid release and its use in the treatment of rheumatic diseases
IL181577A0 (en) Combination therapy composition and methods for the treatment of cardiovascular disorders and immune-related disorders
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
EP1944039A4 (en) ACTIVE AGENT FOR THE TREATMENT OF TUMORS AND ITS USE IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF TUMORS
EP1942911A4 (en) THERAPEUTIC MOLECULES AND USES THEREOF
AP2656A (en) Use of agomelatine in obtaining medicaments intended for the treatment of bipolar disorders

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed